挂一漏万，抛砖引玉。
Gilenya/FTY720：免疫抑制剂。临床用于治疗自身免疫性疾病（如硬皮病）。最早由日
本人提取于冬虫夏草。
On September 22, 2010, fingolimod became the first oral disease-modifying
drug approved by the Food and Drug Administration to reduce relapses and
delay disability progression in patients with relapsing forms of multiple
sclerosis. In 2010 and 2011 it was approved for treating multiple sclerosis
in USA/Russia and Europe/Canada/Australia respectively. It is derived from
the myriocin (ISP-1) metabolite of the fungus Isaria sinclairii.
REF： http://en.wikipedia.org/wiki/Fingolimod#cite_note-13 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754916/?tool=pmcen
其它如来源于雷公藤的Triptolide and tripdiolide在Phase IIb clinical trial（抗
炎及自身免疫性疾病）中结果尚佳。早年我在医学院读/教书时对雷公藤提取物的疗效/
机制颇感兴趣。当时感觉可以成为中药提验单方的一个好课题。
REF： http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017680/
对获N奖可能性的浅见：青蒿素重大影响是基于其用于治疗传染性疾病。与之相比砷剂
治疗M3AML则相对影响力/受益人群较小。更兼ATRA其实是cancer targeted therapy的
第一例。青蒿素可能，而砷剂基本无望。
多年前大连化物所（？）有提取中药单体的大课题，不知现在进行的如何？
